Clinical trial
A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib
NCT00570635 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib
- Lead sponsor
- Exelixis
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- May 31, 2009
- Enrollment
- 16 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.